Diulcus®: A Breakthrough in Diabetic Foot Ulcer Treatment

Diulcus®, developed by NovaLead Pharma, is a new drug showing promising clinical results with a 77.20% ulcer closure rate in treating Diabetic Foot Ulcers. Approved by CDSCO and partially funded by BIRAC, this innovative treatment aims to address the growing diabetes and DFU challenges in India.

Diulcus®, developed by NovaLead Pharma, has shown promising results in clinical trials with a 77.20% ulcer closure rate. Approved by CDSCO and partially funded by BIRAC, the drug aims to address the significant diabetic foot ulcer (DFU) problem in India.

According to a 2023 ICMR-INDIAB study, India has approximately 10 crore people suffering from diabetes and an additional 13.6 crore affected by pre-diabetes. With the launch of Diulcus®, IPCA Laboratories Ltd hopes to tackle the most prevalent complication among diabetics – DFU. Sri. Ajit Jain, Managing Director of IPCA Laboratories, emphasized the importance of this drug in preventing lower limb amputations, a common consequence of chronic diabetes.

During phase 3 trials, Diulcus® showed a 60.3% ulcer closure rate within three months, increasing to 77.20% after six months. Medical experts are optimistic about its potential to revolutionize DFU treatment in India, offering a new lease on life for millions of patients.

(With inputs from agencies.)